Background: Exclusive enteral nutrition [EEN] and corticosteroids [CS] induce similar rates of remission in mild to moderate paediatric Crohn's disease [CD], but differ with regard to mucosal healing. Our goal was to evaluate if EEN at diagnosis was superior to CS for improving long-term outcomes. Methods: We prospectively followed newly diagnosed children aged < 17 years, with mild to moderate CD at baseline, for 2 years in the GROWTH CD study. Patients were evaluated at baseline and at 8, 12, 78, and 104 weeks. Remission, relapses, complications [fibrostenotic disease, penetrating disease, and active perianal disease] and growth were recorded throughout the study. A propensity score analysis was performed. Conclusions: Use of EEN was associated with higher remission rates and a trend toward better growth but with similar relapse and complication rates in new-onset mild to moderate paediatric CD.
Introduction
The goals of therapy in inflammatory bowel diseases include induction of remission and prevention of complications. Most decisions regarding use of medications at disease onset rely on ability to induce remission or maintain remission rather thaability to prevent complications. Current ECCO/ESPGHAN guidelines 1 recommend using exclusive enteral nutrition [EEN] for 6-8 weeks (with or without an immune modulator [IMM] ) as the initial induction of remission therapy in mild to moderate active Crohn's disease [CD] . This was based on clinical studies [2] [3] [4] demonstrating high remission rates with a decline in inflammatory markers, as well as a meta-analysis [5] [6] [7] demonstrating that EEN was equivalent to corticosteroids [CS] for induction of remission, but with fewer side effects. However, recent reports have demonstrated high remission rates but also a high relapse rate during the first year of therapy. 8, 9 Recent studies have demonstrated that EEN may not only induce high rates of remission but may be associated with superior mucosal healing and normal C-reative protein [CRP] remission. 2, 5, 6, [10] [11] [12] [13] We thus hypothesised that use of EEN in mild to moderate CD would be associated with a decreased risk for relapse and early complications. Our goal was to evaluate the outcomes of patients with mild to moderate disease at presentation, in an inception cohort from the GROWTH CD study, treated with either EEN or CS, in order to evaluate if early use of EEN might reduce early complication rates and improve growth.
Methods

Patient population
The GROWTH CD study was a prospective inception cohort that followed newly diagnosed treatment-naïve children with CD, conducted among 17 sites in Europe and Israel, from the Paediatric IBD Porto Group of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition [ESPGHAN] and supported by the European Crohn's Colitis Organisation [ECCO] . The patient population of the present research consisted of consecutive patients with mild to moderate disease, enrolled in the prospective Growth Relapse and Outcomes With THerapy CD [GROWTH CD] study [NIH NCT00711945 ]. This framework study was designed to evaluate and prognosticate different early adverse patient outcomes, such as growth retardation, relapse, complicated disease behaviour, and requirement for surgery, from the first remission, and to evaluate the role of treatment choices on these outcomes. This study was planned a priori to evaluate outcomes related to induction of first remission and the effect of initial therapy on these outcomes, and to evaluate relapse by 78 weeks [ 15 following colonoscopy, gastroscopy, and small bowel imaging. All centres obtained ethical approval, and written consent was obtained from all participants. Patients were subsequently classified by the Paris classification 16 using the location and behaviour of disease from the baseline to the Week 12 visit. In the present study, we included only children with mild-moderate disease who were initially treated with either EEN or steroids to induce remission at diagnosis.
Active disease was defined as a Paediatric Crohn's Disease Activity Index [PCDAI] ≥ 10. Mild to moderate disease was defined as PCDAI > 10 < 40. Steroid-free remission at Week 12 was used to predict long-term outcomes and also to assess the effect of the induction therapy. Remission for this study was rigorously defined by physician's global assessment [PGA] coupled with a PCDAI ˂ 10 at Week 12.
Induction treatment for patients enrolled in to the GROWTH CD study was standardised for all included patients per protocol. Patients could have received any steroid treatment [prednisone or methylprednisolone 1-1.5 mg/kg /day to be tapered by Week 11] , EEN with any formula but exclusively for 6-8 weeks, as well as biologics, antibiotics, and mesalamine. Steroids were to be weaned by Week 12 and those requiring steroids past this time point were considered steroid dependent. Patients included in this study were only those who received EEN or CS at diagnosis.
Patients In order to have rigorous associations, we defined remission as PCDAI < 10 obtained from the original therapy, such that if patients required additional therapy before Week 12 they were considered failing to obtain remission on the original therapy. Height Z score was not incorporated in the PCDAI score for remission at Week 12, since it is not responsive immediately to clinical remission.
We performed a second predetermined analysis among patients who entered remission [to exclude patients who did not obtain remission with their original therapy] and subsequent development of complications. For this second analysis, inclusion criteria included: baseline PCDAI 12.5-37.5; presenting with inflammatory behaviour [B1] and no active perianal disease [defined as draining fistula or abscess]; and in remission at Weeks 8 and 12 with 6-8 weeks of EEN or with CS 1-1.5 mg/kg prednisone [with or without concomitant IMM]. This cohort was chosen to evaluate if there are differences between therapies if patients successfully obtain remission, to reduce confounding factors, and to evaluate new-onset complications that were not present at diagnosis. , according to the distribution of the data. Continuous data were compared by treatment using the Student's t-test for independent samples or the Wilcoxon rank sum test, as appropriate. Categorical data were compared by treatment, using the chi square or Fisher's exact tests as appropriate, and the McNemar test for paired data from matching. For patients with missing data from Week 12, we imputed the last observation carried forward. Any change in therapy was imputed as a failure of the previous therapy. Intention-to-treat analysis was performed using the baseline visit for therapy, and the per-protocol analysis used the medication that actually induced remission, in order to evaluate the long-term outcome of the drug used for remission. The Kaplan-Meier estimator was used to evaluate the time for relapse. Log rank test was used to compare relapse between patient groups. Mean time to relapse was used, as the median was not achieved within the time evaluated. Additional analysis using a propensity score was used to confirm outcomes if there were differences between groups at baseline. All tests were two-sided and considered significant at p < 0.05.
Statistical analysis
Since there were significant differences in baseline characteristics between the two study groups, a propensity score matching was performed to confirm the results; it was calculated using multivariate logistic regression. Variables included in the logistic regression were age, gender, baseline PCDAI, and use of IMM by Week 12, and variables paired included also disease location by the Paris classification and inflammatory markers.
The propensity score was calculated as the probability of treatment with EEN, using logistic regression which included three baseline characteristics that differed between groups at a level of p ≤ 0.1: PCDAI, IMM, and age, which were used for matching. A difference up to 5% was considered acceptable for matching. After matching, the groups were compared using the McNemar test for categorical variables and the paired simple t-test or Wilcoxon signed test for continuous variables. Multivariate conditional logistic regression was used to identify predictors for study outcomes. All tests were two-sided and considered significant at p < 0.05. Time (months) 
Results
Demographic data
P = 0
Propensity-paired samples analysis for outcomes based on therapy
Using the propensity score, 46 matched pairs were obtained. Baseline characteristics after matching were not significantly different between treatment groups [ 
Does treatment make a difference if remission is present?
We subsequently focused our attention on patients with B1 and no perianal [fistula or abscess] disease entering steroid-and biologicfree remission on either therapy, by excluding patients from the same cohort who failed to obtain remission solely with CS or EEN [ Figure 1 ]. Demographic data for this per-protocol remission cohort for analysis are presented in Table 3 .
We had 58 patients who obtained steroid-free remission of PCDAI < 10 with EEN or steroids. Relapse rate within 78 weeks was equal between groups at CS: 
Discussion
This is the first prospective study, to our knowledge, to compare long-term outcomes of therapy, comparing EEN with CS [with or without IMM] as a first-line therapy in mild to moderate CD. Clinical remission is no longer the only goal of therapy. Goals of therapy are sustained clinical remission, prevention of complications, and surgery. Mucosal healing has been associated with these goals, leading this to be an endpoint in clinical studies instead of the patient outcomes it is supposed to generate. Although we hypothesised that the superior mucosal healing and normal CRP remission that have been associated with EEN in other studies would decrease complications and surgery [the primary endpoints], we did not find this to be the case. Complications, time to relapse, and surgery rates did not differ between groups with multivariate analysis or with a propensity score analysis.
However, there appeared to be two treatment advantages associated with EEN. EEN was associated with superior clinical remission rates even after correcting for confounders such as baseline severity and use of IMM, with a propensity score analysis. This superior remission rate did not translate, however, into lower relapse, or complication rates, or biologic use, with multivariate analysis. We did not demonstrate that one group was more likely than another to require biologics in the propensity score analysis. Theoretically, patients who are not in steroid-free remission are more likely to have relapse or complications because of uncontrolled disease and inflammatory activity. However, failure to achieve CS-free remission may have led to use of additional therapy which was effective for remission, and thus there was no difference in relapse. We performed an analysis of patients in both groups in steroid-free remission with inflammatory phenotype [B1 and no perianal disease by the Paris classification]. 16 Though this cohort was smaller, results of relapse [33% both groups] and complication rates [20% and 18%] were identical. This suggests that steroid-free remission may be more important for complications and relapse than the actual therapy used to achieve CS-free remission.
The second apparent benefit was for long-term linear growth, as use of CS [even with thiopurines] was associated with a significant decline in height Z scores, whereas EEN was associated with stable height Z scores over time. This benefit was supported by the results of the propensity score analysis which showed better growth in the matched pairs for patients receiving EEN, though the p-value just about reached significance [p = 0.055]. Our study thus differs from the retrospective study by Grover et al. 17 in which follow-up past 1 year demonstrated decreased rates of growth failure for patients in EEN and increased rates of growth failure with CS. This study did not evaluate mean Z scores, and the cutoff for growth failure was set at -1.64 SD. On the other hand, our data support the findings of Cameron et al. 9 that early use of EEN did not improve Z scores over 2 years. The significant differences noted in our study are not because of improved growth in the EEN group, rather are due to decreased linear growth in the CS group. It is important to note that we chose to evaluate height Z score and not velocity, since velocity is not a complication whereas decrease in height is a complication. We did not register parental height during the study, so we could not correct for mid parental height. Our study reinforces the concept that other therapies, such as EEN or biologics, might be preferable in children with faltering growth.
Based on meta-analysis, Cochrane reviews, and recent clinical studies, 5, 6, 11, 12 current ECCO guidelines now recommend EEN as the recommended first-line therapy for uncomplicated luminal mild to moderate disease in children, based on equivalent remission and superior mucosal healing. 1 We believe that our study is the first to validate these recommendations, based on data other than mucosal healing or safety, and the first to demonstrate superiority for remission prospectively. Our data support this recommendation, since better growth and remission rates without compromising risk for complications is consistent with the preference for EEN over CS as the initial recommended therapy.
The GROWTH CD study enrolled consecutive treatment-naïve patients at diagnosis and was geared to prospectively identify remission, relapse, growth, and early complications within 2 years, which is a time frame that is clinically relevant for decisions at diagnosis regarding initial therapy. Our study has provided more data to suggest that EEN is superior or equivalent to CS, depending on the outcome chosen, using long-term outcomes in a prospective cohort designed for this purpose.
There are limitations to this study, including the fact this was not a randomised controlled trial. Choice of therapy varied between institutions, such that some institutions used more CS for their patients and others used EEN more frequently; this may have led to some bias in outcomes. Detection of complications was driven by patient care, and thus we may have missed silent complications, though this bias is true of previous published studies as well. We could not evaluate biologic therapy as a first choice, since the number of patients treated with this therapy at disease onset was very small.
Previous studies have highlighted advantages of EEN over CS, including linear growth, decreased steroid dependence, and lack of side effects in comparison with CS. 1, [17] [18] [19] On the other hand, EEN is more difficult for parents and patients, and requires more frequent follow-up, and institutional resources. 20 Our study provides additional prospective data comparing these treatments, to allow paediatricians more evidence for clinical decisions in children with CD.
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